Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results

    NEXT STORY
    Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions
    PREV STORY
    Amarin’s John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ascendis Pharma A/S Announces Participation in 36th Annual J.P. Morgan Healthcare Conference

    COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Orion Group Interim Report January-March 2018

    author_avatar
    NASDAQ Market News

    Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma

    Durable Disease Control with Six Month PFS rate of 38.5% and 12 Month PFS ...

    author_avatar
    NASDAQ Market News